DOCSLIB.ORG

Supplemental Table 1: Genes That Show Altered Expression in Hepg2 Cells in the Presence of Exogenously Added Let-7

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 1: Genes That Show Altered Expression in Hepg2 Cells in the Presence of Exogenously Added Let-7 Supplemental Table 1: Genes that show altered expression in HepG2 cells in the presence of exogenously added let-7 Gene Title Gene Symbol RefSeq Transcriptp- IDvalue(TREAp-TMENTvalue(Let7bS) - negativLog2 Reatio control1) (Let7b - negativp-value(Let7be control1) - negativLog2 Reatio control2) (Let7b - negative control2) aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-reductase) AKR1D1 NM_005989 3.28E-12 2.52E-12 -3.85007 3.59E-12 -3.73727 lin-28 homolog B (C. elegans) LIN28B NM_001004317 6.13E-15 8.29E-15 -3.29879 1.55E-15 -3.79656 high mobility group AT-hook 2 /// high mobility group AT-hook 2 HMGA2 NM_001015886 /// NM_0034833.74E-14 /// NM_0034844.29E-14 -3.06085 4.56E-14 -3.04538 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 NM_020760 1.27E-13 6.65E-13 -2.94724 4.47E-12 -2.50907 cell division cycle 25A CDC25A NM_001789 /// NM_2015672.01E-11 7.32E-11 -2.88831 1.99E-11 -3.22735 hypothetical protein FLJ21986 FLJ21986 NM_024913 1.05E-09 5.19E-10 -2.80277 1.18E-09 -2.61084 solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 NM_006931 1.59E-13 3.49E-13 -2.78111 1.84E-12 -2.41734 Transcribed locus --- --- 2.58E-13 1.08E-13 -2.59794 1.69E-13 -2.50248 Hypothetical protein LOC145786 LOC145786 --- 4.23E-12 1.07E-11 -2.58849 3.00E-12 -2.88135 Dicer1, Dcr-1 homolog (Drosophila) DICER1 NM_030621 /// NM_1774381.06E-08 4.37E-09 -2.5442 4.49E-09 -2.53796 mannose-binding lectin (protein C) 2, soluble (opsonic defect) MBL2 NM_000242 9.73E-10 1.48E-09 -2.53211 9.84E-10 -2.62363 cell division cycle 25A CDC25A NM_001789 /// NM_2015677.44E-14 8.65E-14 -2.49891 3.90E-14 -2.67164 hypothetical protein LOC145786 LOC145786 --- 9.68E-11 2.10E-10 -2.49462 6.21E-11 -2.7689 Dicer1, Dcr-1 homolog (Drosophila) DICER1 NM_030621 /// NM_1774382.79E-14 2.51E-14 -2.45436 3.21E-14 -2.40416 haloacid dehalogenase-like hydrolase domain containing 1A HDHD1A NM_012080 9.61E-15 1.00E-14 -2.44389 1.23E-14 -2.40192 Dicer1, Dcr-1 homolog (Drosophila) DICER1 NM_030621 /// NM_1774384.46E-08 2.78E-08 -2.43541 1.49E-08 -2.57479 dual specificity phosphatase 9 DUSP9 NM_001395 8.85E-13 7.63E-13 -2.42489 6.76E-13 -2.4497 solute carrier organic anion transporter family, member 4C1 SLCO4C1 NM_180991 4.23E-10 4.73E-10 -2.41257 9.91E-11 -2.75897 solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 NM_006931 6.99E-14 2.93E-13 -2.37509 1.06E-12 -2.13093 hyaluronan-mediated motility receptor (RHAMM) HMMR NM_012484 /// NM_0124851.53E-11 1.48E-11 -2.35937 8.98E-12 -2.46154 Putative neuronal cell adhesion molecule PUNC NM_004884 1.13E-08 1.31E-08 -2.33991 2.42E-08 -2.21604 aurora kinase B AURKB NM_004217 1.04E-11 9.53E-12 -2.29164 8.71E-12 -2.30913 solute carrier family 2 (facilitated glucose transporter), member 3 /// solute c SLC2A3 /// SLC2A14NM_006931 /// NM_1534492.53E-11 1.17E-10 -2.28343 3.73E-10 -2.06781 pleiomorphic adenoma gene-like 2 PLAGL2 NM_002657 2.13E-12 1.62E-12 -2.25936 1.43E-12 -2.28277 cyclin A2 CCNA2 NM_001237 5.19E-13 4.88E-13 -2.24473 6.29E-13 -2.19724 ubiquitin-like, containing PHD and RING finger domains, 1 UHRF1 NM_013282 6.16E-14 1.70E-13 -2.22165 2.84E-13 -2.12743 tubulin tyrosine ligase-like family, member 4 TTLL4 NM_014640 1.97E-14 1.49E-14 -2.15645 7.76E-15 -2.27775 similar to RIKEN cDNA 1200014N16 gene MGC14289 NM_080660 3.62E-13 7.78E-13 -2.14115 6.29E-13 -2.17971 E2F transcription factor 5, p130-binding E2F5 NM_001951 1.92E-13 1.19E-13 -2.12946 5.24E-13 -1.8803 CDC6 cell division cycle 6 homolog (S. cerevisiae) CDC6 NM_001254 4.82E-13 8.52E-12 -2.12602 7.53E-12 -2.14828 deiodinase, iodothyronine, type I DIO1 NM_000792 /// NM_2135931.70E-09 3.42E-09 -2.123 1.02E-09 -2.35815 denticleless homolog (Drosophila) DTL NM_016448 4.35E-11 6.78E-10 -2.07975 9.03E-10 -2.02875 RAD18 homolog (S. cerevisiae) RAD18 NM_020165 6.73E-09 6.63E-09 -2.07149 5.77E-09 -2.09708 serine/threonine kinase 6 STK6 NM_003600 /// NM_1984332.06E-13 /// NM_1984344.75E-13 /// NM_198435 ///-2.06623 NM_198436 /// 6.77E-13NM_198437 -2.00555 S-phase kinase-associated protein 2 (p45) SKP2 NM_005983 /// NM_0326371.46E-11 3.79E-10 -2.0565 1.90E-10 -2.18265 dopa decarboxylase (aromatic L-amino acid decarboxylase) DDC NM_000790 6.92E-14 3.77E-14 -2.05118 4.33E-14 -2.02728 APin protein APIN NM_017855 7.25E-11 5.75E-11 -2.04877 3.38E-11 -2.14365 DNA replication complex GINS protein PSF2 Pfs2 NM_016095 7.74E-14 3.73E-13 -2.02611 8.01E-13 -1.89993 activator of S phase kinase ASK NM_006716 7.22E-12 4.16E-12 -2.02005 3.28E-12 -2.061 solute carrier family 2 (facilitated glucose transporter), member 3 /// solute c SLC2A3 /// SLC2A14NM_006931 /// NM_1534492.55E-13 3.64E-13 -2.01819 2.97E-12 -1.69067 solute carrier family 35, member F5 SLC35F5 NM_025181 9.35E-11 3.24E-11 -2.01487 6.50E-11 -1.89889 ribonucleotide reductase M2 polypeptide RRM2 NM_001034 2.28E-15 4.66E-15 -2.01117 2.93E-15 -2.09111 CDNA FLJ11381 fis, clone HEMBA1000501 --- --- 3.88E-09 3.07E-09 -2.01062 2.27E-09 -2.06382 hypermethylated in cancer 2 HIC2 NM_015094 1.37E-08 8.34E-09 -2.01005 4.96E-09 -2.1038 Galactosidase, beta 1 GLB1 NM_000404 1.29E-10 1.15E-10 -2.00307 3.31E-11 -2.22704 denticleless homolog (Drosophila) DTL NM_016448 6.33E-15 1.38E-13 -1.99945 9.77E-14 -2.05806 solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 NM_006931 2.27E-12 2.57E-12 -1.99809 1.58E-11 -1.71314 GAJ protein GAJ NM_032117 5.28E-11 5.62E-11 -1.99004 3.34E-11 -2.0803 hypothetical protein LOC253842 LOC253842 --- 5.23E-10 6.50E-10 -1.98709 1.90E-10 -2.20856 putative small membrane protein NID67 NID67 NM_032947 1.09E-08 5.41E-09 -1.9577 5.69E-09 -1.9489 hyaluronan-mediated motility receptor (RHAMM) HMMR NM_012484 /// NM_0124857.93E-10 7.69E-10 -1.9564 3.72E-10 -2.08276 hypermethylated in cancer 2 HIC2 NM_015094 5.01E-11 6.78E-11 -1.95061 9.35E-11 -1.89784 Paternally expressed 3 PEG3 NM_006210 2.40E-09 2.51E-08 -1.94183 1.45E-07 -1.65871 polymerase (DNA directed), epsilon 2 (p59 subunit) POLE2 NM_002692 6.07E-14 8.40E-14 -1.93668 7.40E-14 -1.95732 proteasome (prosome, macropain) activator subunit 4 PSME4 NM_014614 9.93E-07 4.19E-05 -1.93116 2.76E-05 -2.01839 lysyl oxidase LOX NM_002317 8.52E-11 4.31E-08 -1.9294 6.44E-08 -1.8609 zinc finger, CSL-type containing 2 ZCSL2 NM_206831 8.86E-12 1.11E-11 -1.92796 4.35E-12 -2.08693 paternally expressed 3 PEG3 NM_006210 4.00E-09 1.69E-07 -1.92223 3.93E-07 -1.77804 phosphatidylinositol glycan, class A (paroxysmal nocturnal hemoglobinuria) /// p PIGA NM_002641 /// NM_0204721.47E-09 /// NM_0204736.90E-10 -1.91851 7.63E-10 -1.90193 Supplemental Table 1: Genes that show altered expression in HepG2 cells in the presence of exogenously added let-7 chromosome 14 open reading frame 46 C14orf46 NM_001024674 5.54E-11 2.76E-11 -1.91644 6.40E-11 -1.78396 chromosome 7 open reading frame 23 C7orf23 NM_024315 3.17E-13 1.22E-13 -1.916 3.48E-13 -1.75473 solute carrier family 39 (zinc transporter), member 14 SLC39A14 NM_015359 7.43E-06 0.000232616 -1.88947 0.000491779 -1.72679 family with sequence similarity 54, member A FAM54A NM_138419 2.76E-13 4.73E-13 -1.8867 5.36E-13 -1.86698 microtubule associated serine/threonine kinase-like MASTL NM_032844 6.54E-11 1.15E-10 -1.88332 5.66E-11 -2.00108 suppressor of variegation 3-9 homolog 2 (Drosophila) SUV39H2 NM_024670 3.71E-11 2.14E-11 -1.87873 1.38E-11 -1.95024 hypothetical protein MGC13204 MGC13204 NM_031465 1.93E-09 9.57E-10 -1.87292 9.86E-10 -1.8682 apolipoprotein B (including Ag(x) antigen) APOB NM_000384 5.43E-05 0.0286114 -1.86773 0.0284021 -1.87074 ribonucleotide reductase M2 polypeptide RRM2 NM_001034 1.98E-11 1.68E-10 -1.86737 2.02E-10 -1.83802 nucleoporin 98kDa NUP98 NM_005387 /// NM_0163202.33E-12 /// NM_1391312.98E-12 /// NM_139132 -1.86591 4.20E-12 -1.81269 solute carrier family 6 (amino acid transporter), member 14 SLC6A14 NM_007231 1.94E-11 3.56E-09 -1.86071 2.02E-07 -1.29761 MCM10 minichromosome maintenance deficient 10 (S. cerevisiae) MCM10 NM_018518 /// NM_1827511.82E-12 2.79E-11 -1.85807 2.49E-11 -1.87586 ring finger and WD repeat domain 3 RFWD3 NM_018124 2.04E-11 1.60E-11 -1.85037 1.26E-11 -1.8882 coproporphyrinogen oxidase CPOX NM_000097 4.48E-11 5.67E-11 -1.84531 5.30E-11 -1.85604 cell division cycle associated 7 /// cell division cycle associated 7 CDCA7 NM_031942 /// NM_1458101.16E-10 7.53E-11 -1.84512 2.41E-10 -1.67017 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) LSM6 NM_007080 1.18E-10 6.77E-11 -1.83721 6.61E-11 -1.84092 CDC6 cell division cycle 6 homolog (S.
Load more

Recommended publications
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • Unc93b Antibody (Pab)
    21.10.2014Unc93b antibody (pAb) Rabbit Anti -Human/Mouse/Rat Unc93b Instruction Manual Catalog Number PK-AB718-4553 Synonyms Unc93b Antibody: Unc93b1, homolog of C. elegans Unc93 Description The endoplasmic reticulum (ER) protein Unc93b, a human homolog of the C. elegans Unc93 gene, was initially identified by a forward genetic screen using N-ethyl-N-nitrosourea where a histidine- to-arginine substitution in Unc93b caused defects in Toll-like receptor (TLR) 3, 7 and 9 signaling. Unlike Unc93a, another homolog of the C. elegans Unc93 gene whose function is unknown, Unc93b specifically interacts with TLR3, 7 and 9; the histidine-to-arginine point mutation used to identify Unc93b abolishes this interaction. Mice carrying this point mutation are highly susceptible to infection with a number of viruses, indicating that Unc93b plays an important role in innate immunity. Multiple isoforms of Unc93a are known to exist. This antibody will not cross-react with Unc93a. Quantity 100 µg Source / Host Rabbit Immunogen Unc93b antibody was raised in rabbits against a 19 amino acid peptide from near the amino terminus of human Unc93b. Purification Method Affinity chromatography purified via peptide column. Clone / IgG Subtype Polyclonal antibody Species Reactivity Human, Mouse, Rat Specificity Multiple isoforms of Unc93a are known to exist. This antibody will not cross-react with Unc93a. Formulation Antibody is supplied in PBS containing 0.02% sodium azide. Reconstitution During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap.
    [Show full text]
  • 1 ICR-Geneset Gene List
    ICR-geneset Gene List. IMAGE ID UniGene Locus Name Cluster 20115 Hs.62185 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 21738 21899 Hs.78353 SRPK2 SFRS protein kinase 2 21908 Hs.79133 CDH8 cadherin 8, type 2 22040 Hs.151738 MMP9 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase) 22411 Hs.183 FY Duffy blood group 22731 Hs.1787 PHRET1 PH domain containing protein in retina 1 22859 Hs.356487 ESTs 22883 Hs.150926 FPGT fucose-1-phosphate guanylyltransferase 22918 Hs.346868 EBNA1BP2 EBNA1 binding protein 2 23012 Hs.158205 BLZF1 basic leucine zipper nuclear factor 1 (JEM-1) 23073 Hs.284244 FGF2 fibroblast growth factor 2 (basic) 23173 Hs.151051 MAPK10 mitogen-activated protein kinase 10 23185 Hs.289114 TNC tenascin C (hexabrachion) 23282 Hs.8024 IK IK cytokine, down-regulator of HLA II 23353 23431 Hs.50421 RB1CC1 RB1-inducible coiled-coil 1 23514 23548 Hs.71848 Human clone 23548 mRNA sequence 23629 Hs.135587 Human clone 23629 mRNA sequence 23658 Hs.265855 SETMAR SET domain and mariner transposase fusion gene 23676 Hs.100841 Homo sapiens clone 23676 mRNA sequence 23772 Hs.78788 LZTR1 leucine-zipper-like transcriptional regulator, 1 23776 Hs.75438 QDPR quinoid dihydropteridine reductase 23804 Hs.343586 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 23831 Hs.155247 ALDOC aldolase C, fructose-bisphosphate 23878 Hs.99902 OPCML opioid binding protein/cell adhesion molecule-like 23903 Hs.12526 Homo sapiens clone 23903 mRNA sequence 23932 Hs.368063 Human clone 23932 mRNA sequence 24004
    [Show full text]
  • The Nutrition and Food Web Archive Medical Terminology Book
    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Stroke Genetics and Genomics
    Faculdade de Medicina da Universidade de Lisboa Unidade Neurológica de Investigação Clínica PhD Thesis Stroke Genetics and Genomics Tiago Krug Coelho Host Institution: Instituto Gulbenkian de Ciência Supervisor at Instituto Gulbenkian de Ciência: Doctor Sofia Oliveira Supervisor at Faculdade de Medicina da Universidade de Lisboa: Professor José Ferro PhD in Biomedical Sciences Specialization in Neurosciences 2010 Stroke Genetics and Genomics A ciência tem, de facto, um único objectivo: a verdade. Não esgota perfeitamente a sua tarefa se não descobre a causa do todo. Chiara Lubich i Stroke Genetics and Genomics ii Stroke Genetics and Genomics A impressão desta dissertação foi aprovada pela Comissão Coordenadora do Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 28 de Setembro de 2010. iii Stroke Genetics and Genomics iv Stroke Genetics and Genomics As opiniões expressas são da exclusiva responsabilidade do seu autor. v Stroke Genetics and Genomics vi Stroke Genetics and Genomics Abstract ABSTRACT This project presents a comprehensive approach to the identification of new genes that influence the risk for developing stroke. Stroke is the leading cause of death in Portugal and the third leading cause of death in the developed world. It is even more disabling than lethal, and the persistent neurological impairment and physical disability caused by stroke have a very high socioeconomic cost. Moreover, the number of affected individuals is expected to increase with the current aging of the population. Stroke is a “brain attack” cutting off vital blood and oxygen to the brain cells and it is a complex disease resulting from environmental and genetic factors.
    [Show full text]
  • Supplementary Table 1 Genes Tested in Qrt-PCR in Nfpas
    Supplementary Table 1 Genes tested in qRT-PCR in NFPAs Gene Bank accession Gene Description number ABI assay ID a disintegrin-like and metalloprotease with thrombospondin type 1 motif 7 ADAMTS7 NM_014272.3 Hs00276223_m1 Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3 NM_019555.1 Hs00219609_m1 BCL2-associated X protein BAX NM_004324 House design Bcl-2 binding component 3 BBC3 NM_014417.2 Hs00248075_m1 B-cell CLL/lymphoma 2 BCL2 NM_000633 House design Bone morphogenetic protein 7 BMP7 NM_001719.1 Hs00233476_m1 CCAAT/enhancer binding protein (C/EBP), alpha CEBPA NM_004364.2 Hs00269972_s1 coxsackie virus and adenovirus receptor CXADR NM_001338.3 Hs00154661_m1 Homo sapiens Dicer1, Dcr-1 homolog (Drosophila) (DICER1) DICER1 NM_177438.1 Hs00229023_m1 Homo sapiens dystonin DST NM_015548.2 Hs00156137_m1 fms-related tyrosine kinase 3 FLT3 NM_004119.1 Hs00174690_m1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 GRIN1 NM_000832.4 Hs00609557_m1 high-mobility group box 1 HMGB1 NM_002128.3 Hs01923466_g1 heterogeneous nuclear ribonucleoprotein U HNRPU NM_004501.3 Hs00244919_m1 insulin-like growth factor binding protein 5 IGFBP5 NM_000599.2 Hs00181213_m1 latent transforming growth factor beta binding protein 4 LTBP4 NM_001042544.1 Hs00186025_m1 microtubule-associated protein 1 light chain 3 beta MAP1LC3B NM_022818.3 Hs00797944_s1 matrix metallopeptidase 17 MMP17 NM_016155.4 Hs01108847_m1 myosin VA MYO5A NM_000259.1 Hs00165309_m1 Homo sapiens nuclear factor (erythroid-derived 2)-like 1 NFE2L1 NM_003204.1 Hs00231457_m1 oxoglutarate (alpha-ketoglutarate)
    [Show full text]
  • Atypical Solute Carriers
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1346 Atypical Solute Carriers Identification, evolutionary conservation, structure and histology of novel membrane-bound transporters EMELIE PERLAND ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-513-0015-3 UPPSALA urn:nbn:se:uu:diva-324206 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Friday, 22 September 2017 at 10:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Professor Carsten Uhd Nielsen (Syddanskt universitet, Department of Physics, Chemistry and Pharmacy). Abstract Perland, E. 2017. Atypical Solute Carriers. Identification, evolutionary conservation, structure and histology of novel membrane-bound transporters. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1346. 49 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0015-3. Solute carriers (SLCs) constitute the largest family of membrane-bound transporter proteins in humans, and they convey transport of nutrients, ions, drugs and waste over cellular membranes via facilitative diffusion, co-transport or exchange. Several SLCs are associated with diseases and their location in membranes and specific substrate transport makes them excellent as drug targets. However, as 30 % of the 430 identified SLCs are still orphans, there are yet numerous opportunities to explain diseases and discover potential drug targets. Among the novel proteins are 29 atypical SLCs of major facilitator superfamily (MFS) type. These share evolutionary history with the remaining SLCs, but are orphans regarding expression, structure and/or function. They are not classified into any of the existing 52 SLC families.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq Data
    RESEARCH ARTICLE Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq Data David L. A. Wood1*, Katia Nones1, Anita Steptoe1, Angelika Christ1, Ivon Harliwong1, Felicity Newell1, Timothy J. C. Bruxner1, David Miller1, Nicole Cloonan2, Sean M. Grimmond3,1 1 Queensland Centre for Medical Genomics, University of Queensland, Brisbane, Australia, 2 QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia, 3 Translational Research Centre, University of Glasgow, Glasgow, Scotland a11111 * [email protected] Abstract Genetic variation modulates gene expression transcriptionally or post-transcriptionally, and OPEN ACCESS can profoundly alter an individual’s phenotype. Measuring allelic differential expression at Citation: Wood DLA, Nones K, Steptoe A, Christ A, heterozygous loci within an individual, a phenomenon called allele-specific expression Harliwong I, Newell F, et al. (2015) (ASE), can assist in identifying such factors. Massively parallel DNA and RNA sequencing Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq and advances in bioinformatic methodologies provide an outstanding opportunity to mea- Data. PLoS ONE 10(5): e0126911. doi:10.1371/ sure ASE genome-wide. In this study, matched DNA and RNA sequencing, genotyping ar- journal.pone.0126911 rays and computationally phased haplotypes were integrated to comprehensively and Academic Editor: I. King Jordan, Georgia Institute of conservatively quantify ASE in a single human brain and liver tissue sample. We describe a Technology, UNITED STATES methodological evaluation and assessment of common bioinformatic steps for ASE quantifi- Received: February 3, 2014 cation, and recommend a robust approach to accurately measure SNP, gene and isoform Accepted: April 9, 2015 ASE through the use of personalized haplotype genome alignment, strict alignment quality control and intragenic SNP aggregation.
    [Show full text]
  • UNC93A (NM 018974) Human Tagged ORF Clone – RC217002L3
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC217002L3 UNC93A (NM_018974) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: UNC93A (NM_018974) Human Tagged ORF Clone Tag: Myc-DDK Symbol: UNC93A Synonyms: dJ366N23.1; dJ366N23.2; Unc-93A Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC217002). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_018974 ORF Size: 1371 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 UNC93A (NM_018974) Human Tagged ORF Clone – RC217002L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_018974.2 RefSeq Size: 2011 bp RefSeq ORF: 1374 bp Locus ID: 54346 UniProt ID: Q86WB7 Protein Families: Transmembrane MW: 50.1 kDa This product is to be used for laboratory only.
    [Show full text]